Survodutide

Product Overview

Survodutide (BI 456906), developed by Boehringer Ingelheim, is a unimolecular acylated peptide with once-weekly pharmacokinetics. By activating both GLP-1 and glucagon signaling pathways, it provides clinical benefits beyond GLP-1-only therapies: greater weight reduction, increased energy expenditure, and direct hepatic fat content reduction. It is in advanced clinical trials globally.

Mechanism of Action

GLP-1 receptor activation reduces appetite, slows digestion, and supports blood sugar control. Concurrent glucagon receptor activation increases energy expenditure, promotes stored fat breakdown, and stimulates hepatic fat metabolism. The combination addresses both energy intake and expenditure, while GLP-1 counteracts glucagon's glucose-raising effect.

Key Benefits

Superior Weight Loss — Phase 2 participants lost up to 16–19% body weight over 46 weeks, comparable to or greater than leading GLP-1 monotherapies. Dose-dependent response curve.

Improved Body Composition — Weight reduction comes primarily from fat mass with preservation of lean mass. Dual mechanism overcomes metabolic slowdown during weight loss.

Liver Health — Promotes hepatic fat metabolism, showing promise for improving MASH and reducing liver fibrosis through direct glucagon-mediated effects.

Metabolic Health — Blunts post-meal blood sugar spikes, lowers HbA1c, improves lipid metabolism, and reduces cardiovascular risk factors.

References

1. Zimmermann T, et al. BI 456906: discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. *Mol Metab.* 2022;66:101633.
2. Jungnik A, et al. Phase I studies of the safety and pharmacodynamics of the dual GLP-1/glucagon receptor agonist BI 456906. *Diabetes Obes Metab.* 2023;25(4):1011–1023.
3. Kosiborod MN, et al. Survodutide for the treatment of obesity: SYNCHRONIZE-CVOT trial design. *Heart Failure.* 2024;12(12):2101–2109.